We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs.
Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States.
Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham.
IPO Feb. 2016 (NASDAQ: EDIT)
Unlocking the power and potential of CRISPR genome editing technology.
Acquired by Novartis, Feb. 2014
Next-generation immuno-oncology drugs based on T-cell costimulatory targets.
IPO April 2020 (NASDAQ: KROS)
Novel treatments for patients suffering from hematologic and musculoskeletal disorders.